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Two independent cDNA clones corresponding to a 2.7-kilobase (kb) epidermal growth factor receptor
(EGF-R) mRNA were isolated from a rat liver cDNA library. Sequence analysis revealed 100% homology in
the external domain when compared with the full-length rat EGF-R nucleotide sequence and 80 to 90%
similarity relative to the human EGF-R. However, the 3'-terminal sequence of these clones did not match
EGF-R or any other known sequence(s) and was distinct from the 3' end of the 2.8-kb mRNA, which encodes
a truncated EGF-R in A431 cells. The deduced amino acid sequence revealed an open reading frame which is
homologous to the external domain of the EGF-R but which terminates prior to the transmembrane region.
Southern blot analysis of rat genomic DNA indicated that the 3'-terminal sequence of this transcript is derived
from the EGF-R gene. Analysis of a genomic clone containing the 3' end of the 2.7-kb transcript revealed that
this sequence is present as a discrete exon in the mid-region of the receptor gene in proximity to the exon
encoding the transmembrane domain. Introduction of an expression vector containing the truncated EGF-R
cDNA into Chinese hamster ovary (CHO) cells led to the expression of a 95-kilodalton protein which was
detected in conditioned media, by using antisera directed against the EGF-R. A similarly sized protein was also
detected in the media of WB cells, a continuous, nontransformed line of rat hepatic epithelial cells. Northern
(RNA blot) analysis established that the truncated receptor is encoded by a 2.7-kb transcript found in normal
rat liver. Furthermore, Northern analysis of rat poly(A)+ RNA showed that the 2.7-kb EGF-R transcript is
expressed at differing levels in various fetal and adult tissues. These data indicate that alternative splicing of
the EGF-R primary transcript yields a 2.7-kb mRNA which codes for a truncated form of the receptor. This
receptor is secreted by rat hepatic epithelial cells in culture, which suggests that it may be secreted by normal
rat cells or tissues and perhaps serve an as yet unknown physiological function.
Control of cell growth and proliferation involves a com-
plex series of events initiated by the interaction of serum
growth factors with their cell surface receptors. A large
number of these cell surface receptors belong to a family of
growth factor receptors which consist of an extracellular
ligand-binding domain linked to a cytoplasmic domain that
possesses intrinsic tyrosine kinase activity (for current re-
views, see references 3 and 50). One member of this family,
the epidermal growth factor receptor (EGF-R), is a 170-
kilodalton (kDa) glycoprotein that mediates the effects of
both EGF and transforming growth factor alpha. Stimulation
of the EGF-R by these factors leads to a variety of early and
delayed biochemical and physiological responses which re-
sult in the proliferation of target cells (for a review, see
references 3, 4, and 50). Early responses to growth factor
stimulation include protein phosphorylation at tyrosine res-
idues, activation of transport systems, and, in some cell
lines, stimulation of phosphoinositide turnover. This is fol-
lowed several hours later by an increase in specific protein
and RNA synthesis, and by 12 to 18 h, DNA synthesis
ensues. Binding of ligand to the receptor leads to receptor
clustering on the cell surface followed by the internalization
of the growth factor-receptor complex and its subsequent
degradation in lysosomes. The biological role of receptor
internalization and the mechanism through which EGF and
* Corresponding author.
transforming growth factor alpha stimulate DNA synthesis
and cell proliferation are not yet understood.
The EGF-R gene is the cellular homolog of the v-erbB
oncogene (7). This proto-oncogene can be activated by
insertional mutagenesis following avian leukosis virus infec-
tion (11, 23) or as a result of transduction by the avian
erythroblastosis virus (13, 16, 22, 32, 49). In both cases, the
product is a truncated receptor which lacks a ligand-binding
domain and, in the case of avian erythroblastosis virus, it
also lacks the C-terminal autophosphorylation sites (for a
review, see reference 28). The absence of these regulatory
domains could potentially lead to constitutive activation of
the tyrosine kinase and ultimately result in transformation.
Altered forms of the EGF-R gene have also been observed in
a variety of human primary tumors and tumor cell lines of
glial and squamous origin (10, 15, 17, 18, 26, 34, 48). These
alterations, which usually involve amplification of the gene
and which may or may not be accompanied by gene rear-
rangement, result in overexpression of the EGF-R protein.
Both amplification and rearrangement of the EGF-R gene
have been observed in A431 epidermoid carcinoma cells (27,
31, 38, 43, 47). These cells produce an unusually high
number of EGF-Rs in addition to secreting a truncated form
of the protein (9, 45). This truncated receptor correlates with
the expression of a 2.8-kilobase (kb) mRNA which diverges
from the major EGF-R transcripts found in other human cell
types (10.5 and 5.8 kb) at its extreme 3' end (30, 43).
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FIG. 1. Schematic diagram of the human and rat EGF-R cDNA clones. (A) Schematic representation of the rat EGF-R cDNA clones as
compared with the human EGF-R cDNA. The inserts from plasmids pER-t and pER-ts represent duplicate clones of the truncated rat EGF-R.
Clones ER1 and ER2 represent contiguous cDNAs derived from the full-length receptor mRNA. Horizontal lines represent the regions of
homology to the human EGF-R. Stippled boxes represent the divergent sequence at the 3' end of the truncated receptor cDNAs. (B)
Schematic map of the full-length human EGF-R (hEGF-R) cDNA (43). Untranslated sequences are represented by a line; coding sequences
are represented by an open bar. The hatched box at the 5' end of the coding region represents the signal peptide; the black box represents
the transmembrane domain. (n) indicates an unknown number of A residues in the poly(A) tract. The human cDNA clones (64.1 and 64.3)
used as hybridization probes to screen the rat liver cDNA library are represented by horizontal lines.
Analysis of the EGF-R gene in A431 cells had suggested that
the truncated mRNA is created by a gene rearrangement
resulting in the fusion of the 5' portion of the receptor gene
to an unidentified region of genomic DNA (30).
Here, we report the cloning of a similar transcript from a
rat liver cDNA library and provide evidence suggesting that
alternative splicing of the full-length EGF-R transcript in
normal cells generates a truncated form of the receptor. This
truncated form lacks a transmembrane region and is, there-
fore, secreted. We also show that this transcript is expressed
in a variety of normal tissues and that a truncated form of the
EGF-R is expressed and secreted from WB cells, a contin-
uous, nontransformed line of rat hepatic epithelial cells. We
conclude that this truncated receptor from rat liver is neither
the result of a gene rearrangement nor a product of the
transformed phenotype but may, in fact, have a physiologi-
cal function.
MATERIALS AND METHODS
cDNA and genomic cloning. A cDNA library was prepared
as described previously (24) from mRNAs derived from rat
liver by using a XgtlO vector system. The library was
screened with 5'- or 3'-encoding human EGF-R cDNAs
(clones 64-1 and 64-3, respectively; kindly provided by A.
Ullrich; see Fig. 1 for schematic representation). Four
positive clones were obtained (0.7, 1.6, 2.2, and 2.3 kb in
size) and subcloned into pEMBL (plasmids pER2, pER-ts,
pER1, and pER-t, respectively). Plasmid DNA was purified
by CsCl centrifugation, and the cDNA inserts were se-
quenced by the dideoxynucleotide chain termination method
(35). Plasmid pMB122.6ER was made by ligating the 2.3-kb
rat EGF-R insert from pER-t into the EcoRI site of the
retroviral expression vector pMB122.6 (kindly provided by
R. Snodgrass), which also contains the bacterial neomycin
resistance gene.
A rat genomic library produced in bacteriophage Charon
4A (CLONTECH) was screened in duplicate with the 3' 1.2
kb of cDNA clone ER-ts and a 32P-labeled oligonucleotide,
specific for the 3'-terminal end of ER-t and ER-ts (Fig. 2;
nucleotides 2259 to 2308). Bacteriophage DNA was prepared
and sequenced as previously described (41).
Cells and transfections. CHO cells were grown in Eagle
minimal essential medium with 10% bovine calf serum.
Transfections were by the calcium phosphate precipitation
method as previously described (14, 46). The cells were
subsequently selected with genetecin G418 (0.5 ,ug/ml;
GIBCO). Resistant colonies were picked after 2 weeks and
screened for EGF-R mRNA expression by Northern (RNA)
blot analysis. Positive clones were tested for expression of
truncated EGF-R by immunoprecipitation of [35S]cysteine-
or [35S]methionine-labeled receptors from conditioned me-
dia or tunicamycin-treated cells, with an antiserum (Ab 1382)
to the rat EGF-R.
RNA and DNA blot analysis. Total cellular RNA was
isolated from confluent CHO cells grown on 100-mm plates
by the method of Glisin et al. (12). Cells were lysed in
guanidinium isothiocyanate, and the resulting lysates were
centrifuged over a CsCl cushion. RNA from rat liver, uterus,
decidua, and embryo was isolated by the method of Chirg-
win et al. (5), and poly(A)+ was selected by chromatography
on oligo(dt) cellulose. Total RNA (40 ,ug) or poly(A)+-
selected RNA (5 ,ug per lane) was subjected to 1.0% agarose
gel electrophoresis in formamide and was transferred to
nitrocellulose (42). The RNA blots were probed with human
EGF-R clones 64.1 and 64.3, nick-translated cDNA inserts
from pER-ts, pER1, and pER2, or an end-labeled 50-base-
pair (bp) synthetic oligonucleotide specific to the 3' end of
EGF-R clone ER-t.
DNA isolated from Sprague-Dawley rat liver cells (10 to
20 ,ug) was digested with the appropriate restriction en-
zymes, subjected to 0.7% agarose gel electrophoresis, and















M R P S G T A R T K L L L L L A
20 30 40
TGCGCTCTGCGCCGCAGGTGGGGCGCTGGAGGAAAAGAAAGTTTGCCAAGGCACATACAQGGCTCACCCAACTAGGCACCTTTGAAGACCACTTTCTG
A L C A A G G A L B E KK V C Q G T S N R L T Q L G T F E D H F L
K
50 60 70 80
AGCCTCCAGAGGATGTTCAACAACTGTGAAGTGGTCCTTGGAAACTTGGAAATCACCTATGTGCAAGGAATTATGACCTTTCCTTCTTAAAGACCATCC
S L Q R M F N N C E V V L G N L E I T Y V Q R N Y D L S F L K TI Q
90 100 110
AGGAGGTGGCTGGCTATGTTCTCATTGCCCTGAACACCGTAA TCCCTTTGGAGAACCTGCAGATCATCAGGGGAAATGCTCTCTACGAAAACAC




Y A L A V L S N Y G T N K T G L R E L P N R N L Q E I L I G A V R
D A K H
1S0 160 170 180
TTTAGCAACAACCCCATCCTCTGCAATATGGAGACCATCCAGTGG CGTCCAAGATGTCTTTCTGAGCAACATGTCAATGGACGTACAGCGCC
F S N N P I L C N M E T I Q W R D I V Q D V F L S N M S M D V Q R H
A V S S S D F N
190 200 210
ACCTGACGGGCTGCCCGAAATGTGATCCGAGCTGTCCCAATGGAAGCTGCTGGGGAGAGAGAGGAGAACTGCCAGAAATTGACCAAAATCATCTGCGC
L T G C P K C D P S C P N G S C W G R G EE N C Q K L T K I I C A
G S Q A
220 230 240
CCAGCAATGTTCCCGGCGTTGTCGTGGCAGGTCCCCTAGCGACTGCTGCCACAACCAGTGTGCCGCAGGGTGTACAGGGCCCAGAGAGAGTGACTGTCTG
Q Q C S R R C R G R S P S D CC H N Q C A A G C T G P R E S D C L
G K




















E V E E D G V S K C K K C D G P C R K V C N G I G I G E F K D T L
M R E S
350 360 370 380
TCCATAAATGCTACAAACATCAAACACTTCAAGTACTGCACTGCCATCAGTGGGGACCTCCACATCCTGCCAGTGGCCTTTAAGGGGGATTCTTTCACCC 1300
S I N A T N I K H F K Y C T A I S G D L E I L P VAF K G D S F T R
N S R H
390 400 410
GCACTCCTCCTCTAGACCCACGGGAACTAGAAATTCTCAAAACTGTGAAGGAAATAACAGGGTTTTTGCTGATTCAGGCTTGGCCTGzAAAAC=TGGACTGA 1400




L H A F E N L E I I R G R T K Q H G Q F S L A V V G L N I T S L G
S
450 460 470 480
TTGCGTTCCCTCAAGGAGATCAGTGATGGGGATGTGATTATTTCTGGGAACCGAAATTTGTGCATCGCAAACACTATAAACTGGAAAAAACTCTTCGGGA 1600




P N Q K T K I M N N R A EK D C K A T N H V C N P L C S S E G C W
S G I S G N S G Q H A P
520 530 540
GGGCCCTGAGCCCACGGACTGTGTCTCCTGCCAGAATGTGACAGAGCAGGGAGTGCGTGGACAAGTGCAACATCCTGGAG=GAACCGAGGGAGTTT 180 0
G P E P T D C V S C Q N V S R G R E C V D K C N I L E G E P R E F
R R K L
550 560 570 580
GTGGAAAATTCTGAATGCATCCAGTGCCATCCAGAATGTCTGCCCCAGACCATGAACATCACCTGTACAGGCCGGGGGCCAGACAACTGCATCAAGTGTG 19100




H Y V D G P H C V K T C P S G I M G E N N T L V W K F A D A N N V
I A V Y G H
620 630 §40 V
CTGCCACCTCTGCCATGCAAACTGTACCTATGGATGTGCTGGGCCAGGCCTTAAAGGATGTCXAACCAAAGGt tccaactattgattgaaatgctgc 2100
C H L C H A N C T Y G C A G P G L K G C Q Q P E G S N Y END
P T E * P T N
ccagaggaacattaaattatggatgaatttccgtt cagagccttcatgcaacagaggtgtcagcaagcagcat ctagtgcagaattgagattgtctacaa 22200
aatgcctgcctgatgctcgggcttgtaccccagtcatggacatgtctacaactatccctccccttacctcccttccttaacttcatactatggtgactga 2300
tcccttctgctgtcaactgaaatagtaaaatataaaaaagccttgtcc (A)18 2348
FIG. 2. Nucleotide and predicted amino acid sequence of the truncated rat EGF-R. The numbers on the right correspond to the nucleotide
sequence; the amino acid sequence is numbered throughout. Nonmatching amino acids in the human receptor are shown throughout the
region of homology between the full-length and truncated receptors. Lowercase letters are used to indicate the region of the truncated
receptor which is nonhomologous to the full-length receptor. The arrowhead indicates the point at which the homology between the full-length
and truncated receptors ends. Nucleotide deletions in the human receptor sequence are indicated by black dots, and the star indicates an
amino acid deletion. The polyadenylation signal and the 50-bp oligonucleotide used for Northern analysis and genomic cloning are
underscored.
The DNA blots were probed with nick-translated cDNA or containing 10 ,ug of tunicamycin per ml were added to the
insert from pER1 or pER-t. appropriate plates 1 h prior to the addition of label. Forty
Immunoprecipitation. CHO cells were grown to conflu- microcuries of [35S]cysteine or [35S]methionine per ml (Du-
ence on 35-mm plates. WB cells were grown to confluence Pont, NEN Research Products) was then added, and the
on 100-mm plates. Cysteine- or methionine-free media alone cells were incubated for 2 to 3 h. The media from all plates
2976 PETCH ET AL.
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FIG. 3. Comparison of the human and rat full-length and truncated receptors at the junction of nonhomology. The arrow points to where
the homology between the full-length and truncated receptors ends. The beginning of the transmembrane domain is underscored. (A)
Nucleotide sequence comparison. Lowercase letters are used to indicate the divergent sequence of the truncated receptor. Dots represent
identical nucleotides, and the nucleotide deletions in the human receptors are indicated by stars. (B) Amino acid sequence comparison. The
italicized amino acids correspond to the divergent region of the truncated receptors. Dots represent identical amino acid residues, and the
parentheses indicate the amino acid deletion. h-EGF-R, Human EGF-R; r-EGF-R, rat EGF-R.
were collected and, following detergent lysis of the cells,
centrifugation, and preclearance of supernatants with nor-
mal rabbit serum and Pansorbin, the cells and media were
immunoprecipitated as described previously (8). The poly-
clonal anti-rat EGF-R antiserum (Ab 1382) was raised in
rabbits against purified rat liver EGF-R (8). Immunoprecip-
itates were boiled in electrophoresis sample buffer contain-
ing sodium dodecyl sulfate and were subjected to 7% poly-
acrylamide gel electrophoresis. Gels were treated for 1 h
with 1 M sodium salicylate and, after drying, were exposed
to Kodak XAR film.
RESULTS
Cloning of EGF-R cDNAs. The isolation and characteriza-
tion of a cDNA encoding a truncated form of the EGF-R in
A431 epidermoid carcinoma cells have been previously
described (43). This transcript was attributed to a rearrange-
ment of the EGF-R gene in these cells. Here, we report the
isolation of a similar cDNA encoding a secreted form of the
EGF-R from normal rat liver. A rat liver cDNA library was
screened with the human EGF-R clones 64-1 and 64-3 as
hybridization probes. Positive clones were isolated and
subcloned into the EcoRI site of pEMBL. Four of these were
further analyzed by dideoxy sequencing. Comparison of the
complete sequence of clone ER1, and a partial sequence of
ER2 (see Fig. 1 for schematic representation), with that of
the human EGF-R (43) revealed an overall similarity of 80 to
90%. Relative to the human receptor sequence, the 2.1-kb
insert in plasmid pER1 extends from within the 5' untrans-
lated region to nucleotide 2317, 92 bp downstream from the
end of the transmembrane coding region. The 0.7-kb EcoRI
insert in plasmid pER2 extends from nucleotide 2318 to
nucleotide 3085, spanning the tyrosine kinase domain of the
EGF-R. Clones ER1 and ER2 are, therefore, contiguous and
represent >80% of the coding region of the EGF-R.
Nucleotide and amino acid sequence analysis. Examination
of the nucleotide sequence of cDNA inserts ER-t and ER-ts
revealed that they are independent clones derived from the
same RNA. ER-ts, however, lacks 700 nucleotides from the
5' terminus. The 2.3-kb insert in plasmid pER-t contains 153
bp of 5' untranslated sequence and spans almost the entire
extracellular domain of the receptor (Fig. 2 and 3). Relative
to the membrane-spanning receptor cDNA ER1, the se-
quence homology of the two truncated cDNA clones de-
clines abruptly at nucleotide 2105, immediately prior to the
transmembrane domain. This is followed by a stretch of 273
nucleotides which is identical in clones ER-t and ER-ts but
which shares no homology with either rat or human EGF-R
sequences. Furthermore, this stretch of sequence is distinct
from the 3'-terminal sequence of the 2.8-kb transcript found
in A431 cells (43). A computer search of sequences in
GenBank and EMBL revealed no similarity to any other
known sequences.
The predicted amino acid sequences of the membrane-
spanning (ER1) and truncated (ER-t) EGF-R cDNAs reveal
an open reading frame whose initiator methionine corre-
sponds to the methionine at position -24 in the signal
peptide of the human EGF-R (43). The sequence of clone
ER-t is identical to that of clone ER1 through amino acid
position 641, at which point the sequence homology declines
(Fig. 2 and 3). From residue 641, the open reading frame of
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3 4 RNA. However, Northern analysis of poly(A)+ rat liver
RNA with the human cDNA specific for the external domain
1 9.62 of the receptor (64.1) as a hybridization probe revealed the
9.6 - 6.5 5 presence of an additional 2.7-kb receptor mRNA. This
6.5 - 5 0 transcript was not observed when the cDNA specific for the
5.0_" w tyrosine kinase domain (64.3) was used (data not shown). A
2.7_-.....2.7-kb transcript is insufficient in size to code for the
7.
full-length EGF-R whose coding region alone spans approx-
2.7_ * " imately 3.6 kb. To determine whether the truncated receptor
cDNA described above is derived from this 2.7-kb mRNA,
we carried out Northern blot analyses of poly(A)+ rat liver
RNA with the rat cDNA clones as hybridization probes.
Only the three larger EGF-R transcripts were detected with
the insert from plasmid pER2, which, by comparison to the
human EGF-R sequence, is specific for the cytoplasmic
tyrosine kinase domain (Fig. 4, lane 1). However, all four
EGF-R transcripts were detected by clone ER-ts (Fig. 4,
FIG. 4. Northern blot analysis of rat liver poly(A)+ RNA. lane 2), which contains both homologous and 3' divergent
Poly(A)+ RNA was prepared, and samples (5 ,ug) were electro- sequences. The same result was obtained with clone ER1,
phoresed through 1% agarose gels containing formaldehyde. RNA which is specific for the external and transmembrane domain
was transferred to nitrocellulose and was probed with nick-trans- coding regions (Fig. 4, lane 3). These data show that the
lated EcoRI inserts (Fig. 1) from plasmids pER2 (lane 1), pER-ts 2.7-kb mRNA in rat liver shares 5' sequences, but not 3'
(lane 2), and pER1 (lane 3) or with an end-labeled 50-bp oligonucle-
otide (Fig. 2) specific for the 3'-end clones ER-t/ER-ts (lane 4). The sequences, with the three larger receptor transcripts. This,
numbers indicate (in kilobases) the size of the receptor transcripts. in addition to the sequence data described above, suggests
that clones ER-t and ER-ts, which lack the sequences coding
for the transmembrane and cytoplasmic domains of the
another three amino acids and is then followed by a stop EGF-R are derived from the shorter, 2.7-kb receptor tran-
codon (TGA) and a 260-bp, 3' untranslated sequence, which script. On the basis of the size discrepancy between the
includes a polyadenylation signal (AATAAA) 15 nucleotides 2.3-kb ER-t cDNA and the 2.7-kb receptor transcript, it
upstream from the polyadenylation site. appears that the former is not a full-length clone. It is not
A comparison of the amino acid sequence of the external clear, however, whether the ER-t cDNA is missing 5' or 3'
domain of the rat and human EGF-R revealed an overall sequences or whether the 2.7-kb mRNA contains an unusu-
similarity of 94% when taking into account the fact that ally long poly(A) tract. To confirm that the ER-t and ER-ts
approximately one-half of the amino acid differences are cDNAs are derived from the 2.7-kb mRNA, a 50-bp oligo-
conservative substitutions. Furthermore, alignment of these nucleotide, complementary to the 3' terminus of clone ER-t,
sequences through amino acid 636 (nucleotide 2061) revealed was synthesized and used for Northern analysis. Only the
no deletions or insertions in either sequence (Fig. 2 and 3). 2.7-kb transcript was detected with the oligonucleotide
Thus, all amino acid differences occurring throughout this probe (Fig. 4, lane 4). Furthermore, this oligonucleotide
region reflect base substitutions. However, immediately failed to hybridize to poly(A)+ RNA from human A431 cells
prior to the transmembrane domain of the human EGF-R, (data not shown), consistent with the sequence data that
three nucleotide deletions occur within a 9-bp stretch of the indicate that the rat and human truncated receptor tran-
sequence (Fig. 2 and 3A). This results in three amino acid scripts possess distinct 3' termini. The fact that the oligonu-
changes and the loss of an amino acid from the otherwise cleotide probe, which is specific for the 3' terminus of clone
highly conserved human receptor sequence (Fig. 3B). Inter- ER-t, hybridized only to the 2.7-kb EGF-R transcript pro-
estingly, these three nucleotide deletions and the resulting vides additional evidence supporting the conclusion that the
amino acid changes occur immediately upstream from the variant sequence is unique to the EGF-R gene.
point at which the sequence similarity between the truncated Exon-intron analysis. A rearrangement of chromosome 7
and full-length receptors ends. has been postulated as the mechanism responsible for the
Southern blot analysis. To determine whether the 3' termi- generation of a truncated form of the EGF-R in human A431
nal sequence of cDNA clone ER-t is unique to the EGF-R cells (30). However, the data obtained thus far suggest that
gene, we carried out Southern blot analysis of rat genomic in normal rat liver cells, alternative splicing of the EGF-R
DNA with this cDNA as a hybridization probe. Three major gene is the mechanism by which this structural diversity is
bands (5.1, 3.3, and 1.0 kb) were consistently observed in generated. To investigate this possibility, a rat genomic
XbaI-digested DNA with additional DNA fragments of 13.2, clone was isolated with both a truncated receptor-specific
11.0, 4.2, and 1.8 kb variably detected. Hybridization to oligonucleotide and a 1.2-kb fragment of clone ER-t that
EcoRI-digested genomic DNA consistently revealed a 3.3-kb contains both homologous and nonhomologous receptor
fragment. Additional bands (12.0, 8.8, 4.5, 2.4, and 2.2 kb) sequences. Sequence analysis was carried out with the
were also occasionally detected. Identical restriction pat- synthetic oligonucleotide primers shown in Fig. 5, and
terns were observed when either XbaI- or EcoRI-digested exon-intron junctions were identified by comparing genomic
DNA was probed with the cDNA clone ER1 (data not and cDNA sequences. The position of exons relative to each
shown). These findings confirm that the 3'-terminal sequence other was determined by analysis of the amplified products
of the truncated form of the EGF-R is present as a single of the polymerase chain reaction carried out with these same
copy sequence within the rat EGF-R gene. primers (Fig. 5). The sequence data obtained confirm that
Analysis of EGF-R mRNA expression. EGF-R synthesis in the 3'-terminal sequence of the truncated EGF-R is present
rat liver correlates with the detection of one major (9.6 kb) as a specific exon in the EGF-R gene. These data also
and two minor (6.5 and 5.0 kb) species of RNA in total liver revealed that the last exon shared by the full-length and
VOL. 10, 1990
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FIG. 5. Partial map of the exon-intron structure of the EGF-R gene and the splicing events which generate the truncated or full-length
receptor transcripts. Exons A and B represent the last two exons shared by both the truncated and full-length receptors. The arrow indicates
the junction of nonhomology between the full-length and truncated receptor transcripts. The stippled boxes represent the exon coding for the
3' terminus of the 2.7-kb receptor transcript. The stop codon and polyadenylation signal are shown. The exon labeled TM contains the
transmembrane region of the full-length EGF-R. The synthetic oligonucleotides used to sequence the rat genomic clone are labeled Gl through
G6. The hatched boxes at the 5' end of the coding region represent the signal peptide; the black box represents the transmembrane domain.
The truncated receptor transcript resulting from one splicing event is shown at the top (a). The full-length receptor transcript resulting from
the alternate splicing event is shown at the bottom (b). Numbers indicate (in kilobases) the approximate sizes of the introns.
truncated receptors consists of a 41-bp mini-exon that en-
codes the 14 amino acids at the C-terminal end of the
extracellular domain (Fig. 5). It is interesting to note that the
deletions observed when comparing the external domains of
the human and rat receptors occur entirely within this
mini-exon. Although this could be ascribed to a species
difference, it also raises the possibility that there are EGF-R
isoforms resulting from additional splicing events. For ex-
ample, alternative splicing of a mini-exon generates isoforms
of the human insulin receptor which differ in sequence at the
C-terminal end of the insulin-binding a-subunit (36, 37). As
to the position of the rat EGF-R exons, the results obtained
from the polymerase chain reaction analysis (Fig. 5) suggest
that the ER-t-specific exon is preceded by the external
domain mini-exon and lies upstream of that which codes for
the transmembrane domain. As shown schematically in Fig.
5, use of the ER-t-specific exon would result in the genera-
tion of a truncated EGF-R lacking transmembrane and
intracellular receptor sequences.
Heterologous expression of the truncated receptor in CHO
cells. To determine whether the 2.7-kb transcript can indeed
direct the synthesis of a truncated EGF-R protein, an
expression vector containing the ER-t cDNA was introduced
into CHO cells, which do not express EGF-Rs. The cells and
conditioned growth media were subsequently analyzed for
expression of this truncated protein by immunoprecipitation
with antibody 1382, which recognizes the rat EGF-R. Immu-
noprecipitation of parental CHO cells labeled in the presence
of tunicamycin, with normal rabbit serum or antibody 1382
(Fig. 6, lanes A and B, respectively), failed to reveal a
specific EGF-R-related protein. However, immunoprecipita-
tion of stably transfected cells (CHO-8), labeled in the
presence of tunicamycin, revealed a 65-kDa protein specifi-
cally recognized by antibody 1382 (lanes C and D). A protein
CHO CHO-8
A B C D
9-;S
CHO CHO-8
CHO CHO-8 media media
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FIG. 6. Immunoprecipitation of the truncated EGF-R. CHO
cells transfected with an expression vector containing cDNA clone
ER-t were analyzed for expression of the truncated form of the
EGF-R by immunoprecipitation of the cell lysates and conditioned
media. The arrows indicate the migration of the truncated receptor
protein. Control CHO (lanes A and B) or stably transfected CHO-8
(lanes C and D) cells were labeled with [35S]cysteine (lanes A
through D) or [35S]methionine (lanes E and F) in the presence of
tunicamycin. Cell lysates were immunoprecipitated as described
previously (8) with normal rabbit serum (lanes A and C) or antise-
rum 1382 (lanes B and D). Media conditioned by control (lanes G
through I) or transfected (lanes J through L) cells, labeled with
[35S]cysteine in the presence (lanes G and J) or absence (lanes H, I,
K, and L) of tunicamycin, were immunoprecipitated by normal
rabbit serum (lanes H and K) or antiserum 1382 (lanes G, I, J, and
L). Conditioned media from WB cells labeled in the absence of
tunicamycin were immunoprecipitated with normal rabbit serum
(lane M) or antiserum 1382 (lane N).
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FIG. 7. Expression of the truncated rat EGF-R (rEGF-R) during
rat development. Northern blot analysis of poly(A)+ RNA from
uterus (U), decidua (D), placenta (P), and embryo (E) at various
times during gestation probed with cDNA clone ER-ts (Fig. 1) or
actin. Arrows indicate the migration of the various EGF-R tran-
scripts. Sizes are indicated in kilobases.
of similar size was also immunoprecipitated in these cells by
normal rabbit serum (lane C). This protein appeared to be
nonspecifically recognized, however, as evidenced by its
presence in control cells immunoprecipitated with either
normal rabbit serum or antibody 1382 (lanes A and B,
respectively). Furthermore, this protein was not observed
under all conditions. Immunoprecipitation with antibody
1382 of tunicamycin-treated CHO cells, labeled with
[35S]methionine, failed to reveal any proteins in this size
range (lane E). However, a 65-kDa protein was detected by
antibody 1382 in CHO-8 cells labeled with [35S]methionine in
the presence of tunicamycin (lane F).
Nucleotide and amino acid analysis of cDNA clone ER-t
predicts it would encode a truncated form of the EGF-R
which, because of the absence of its transmembrane and
cytoplasmic domains, would be secreted. To test this hy-
pothesis, we immunoprecipitated media conditioned by con-
trol and transfected cells. No EGF-R-related protein was
detected in media conditioned by either tunicamycin-treated
or untreated parental CHO cells (Fig. 6, lanes G and I,
respectively). Furthermore, no receptor-related protein was
detected in media conditioned by transfected cells treated
with tunicamycin for 1 h prior to the addition of label (lane
J). However, a 95-kDa protein was specifically detected by
antibody 1382 in media conditioned by transfected cells
labeled in the absence of tunicamycin treatment (lane L).
These data suggest that the truncated form of the EGF-R is
synthesized as a 65-kDa precursor that is subsequently
secreted as a 95-kDa glycoprotein. To investigate whether
this protein is synthesized by cells known to express the
2.7-kb EGF-R transcript, we immunoprecipitated media
conditioned by WB cells, a nontransformed rat hepatic
epithelial cell line. To compensate for the reduced level of
expression of the truncated receptor in WB cells versus that
in transfected CHO cells, five times the amount of media was
used for the immunoprecipitation. A 95-kDa EGF-R-related
protein is secreted by these cells (Fig. 6, lane N). Thus, this
truncated form of the EGF-R does not reflect the trans-
formed phenotype but is, in fact, secreted by normal prolif-
erating epithelial cells known to express the 2.7-kb tran-
script.
Previous studies have demonstrated that the truncated
EGF-R secreted by human A431 cells binds EGF, albeit with
a lower affinity than does the full-length receptor (1, 45).
Preliminary cross-linking experiments show that a 95-kDa
protein, present in media conditioned by transfected but not
parental CHO cells, is specifically labeled by [1251]-EGF and
recognized by antibody 1382 (data not shown).
Expression of EGF-R mRNAs in development. The expres-
sion of EGF and its receptor in development has been
extensively studied (D. C. Lee and V. K. M. Han, in M. B.
Sporn and A. B. Roberts, ed., Handbook of Experimental
Pharmacology, in press). Therefore, it was of interest to
examine the expression of the 2.7-kb transcript during de-
velopment. This transcript appears to be expressed at vary-
ing levels, during early gestation, in both the uterus and
decidua, with the highest level of expression occurring in the
decidua at day 10 (Fig. 7). In contrast, expression of receptor
transcripts was not detected in fetal tissue until day 14, at
which time the full-length transcripts, but very low levels of
the 2.7-kb mRNA, were detected. With respect to adult
tissues other than rat liver, EGF-R transcripts, including the
2.7-kb mRNA, were observed in lung tissue (data not
shown).
DISCUSSION
The data presented here indicate that, in addition to the
full-length EGF-R transcripts, normal rat liver cells express
a shorter, 2.7-kb receptor mRNA. This transcript, generated
by alternative splicing of the primary receptor mRNA, is
homologous to the full-length EGF-R throughout the exter-
nal hormone binding domain but lacks the transmembrane
and tyrosine kinase domains and instead possesses a distinct
273-bp sequence at its extreme 3' end. This divergent
sequence introduces an in-frame stop codon immediately
prior to the transmembrane region, generating a truncated
EGF-R protein. As predicted, expression of cDNA clones of
this transcript in CHO cells results in secretion of a 95-kDa
protein which is recognized specifically by antisera against
the rat EGF-R. Our results also indicate that a similarly sized
protein is secreted by WB cells, a line of normal rat hepatic
epithelial cells, which also express the truncated 2.7-kb
EGF-R mRNA.
Altered expression of the EGF-R has been observed in
several human tumors and tumor cell lines. For example, a
receptor-related protein similar in size to this truncated
receptor was recently observed in two human neuroblas-
toma cell lines (2). In addition, A431 human epidermoid
carcinoma cells, which contain amplified and rearranged
copies of the EGF-R gene, express an unusually high num-
ber of EGF-Rs and secrete a truncated form of the receptor
(9, 30, 43, 45). This truncated species is encoded by a 2.8-kb
mRNA which is overexpressed in these cells (30, 43). It was
proposed that this transcript is a hybrid RNA, resulting from
an internal rearrangement of chromosome 7, in which the 5'
portion encoding the outer domain of the EGF-R has been
fused with unidentified DNA and subsequently amplified
(30). It was, therefore, surprising to find that normal rat liver
cells, in which the EGF-R gene is neither rearranged nor
amplified, express a 2.7-kb mRNA which shares 5', but not
3', sequences with full-length EGF-R transcripts. A short
transcript of similar size was also recently observed while
studying EGF-R expression during rat liver regeneration
(20). One possible explanation for the generation of this
transcript is that this RNA is transcribed from a distinct, but
related, gene. For example, a second platelet-derived growth
factor receptor gene, which encodes a receptor exhibiting
distinct platelet-derived growth factor binding characteris-
tics, was recently described (29). Evidence has also been
presented for multiple prolactin receptor mRNAs which
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appear to be encoded by at least two genes (6). That the
truncated form of the EGF-R is not the product of a different
gene is suggested by several lines of evidence. First, the
full-length and truncated rat EGF-R clones are completely
homologous throughout the external domain. Second,
Southern blot analysis of rat liver genomic DNA with both
the membrane spanning and truncated cDNAs confirms that
the respective sequences are unique in the rat genome.
Finally, sequence and polymerase chain reaction analyses of
a rat genomic clone reveal that the point at which the
full-length and truncated receptors diverge corresponds to
an exon-intron junction. These results confirm, therefore,
that the 3'-terminal end of the 2.7-kb transcript is present as
a distinct exon in the EGF-R gene and that the truncated
transcript is not the product of a different gene but is rather
the result of alternative splicing of the primary EGF-R
transcript.
The aforementioned results raise the possibility that the
2.8-kb A431 transcript is similarly generated by alternate
splicing of unrearranged gene sequences. This hypothesis
would not be inconsistent with previous data, which suggest
that a chromosomal rearrangement gives rise to a truncated
form of the EGF-R in A431 cells (30). Although the observed
rearrangement was found to be associated only with a
translocation marker chromosome (M4) present in these
cells, it was not clear from these results whether the pres-
ence of this chromosome is responsible for the expression of
the truncated receptor. Results obtained with mouse-human
somatic cell hybrids do indicate, however, that this abnor-
mal chromosome is clearly responsible for the hyperproduc-
tion of the EGF-R in A431 cells (38). It may also be
responsible, therefore, for the overexpression of the trun-
cated form of the EGF-R. Thus, it is possible that the
observed rearrangement simply reflects the marker chromo-
some-associated alteration(s) involved in the amplification of
the EGF-R gene as a whole rather than structural alterations
within the gene itself. The hypothesis that the truncated
EGF-R is a normal product of the EGF-R gene is further
supported by the finding that the point at which the full-
length and truncated cDNAs diverge is identical in both
humans and rats. Although the 3' termini of the normal rat
and human truncated receptor transcripts are apparently
unrelated, this may simply reflect a lack of conservation
among 3' sequences which are largely noncoding. However,
the possibility that the truncated EGF-R transcript is gener-
ated by a fortuitous splicing event, resulting from a rear-
rangement that juxtaposed the human exon B near a splice
acceptor of another gene on chromosome 7 or led to the
interruption of the normal receptor sequence by a novel
DNA sequence, cannot be excluded.
The 2.7-kb EGF-R transcript is readily detected in rat liver
mRNA, and its protein product is obviously produced and
secreted by liver epithelial cells. In addition to rat liver, we
have detected low-level expression of a 2.7-kb EGF-R
mRNA in lung tissue and varying levels of expression in the
uterus and decidua of pregnant rats. Although the truncated
receptor transcript has only been observed in conjunction
with the full-length receptor mRNAs, the expression of these
transcripts is not always coregulated. For example, a signif-
icant elevation of the 2.7-kb transcript was observed relative
to the full-length EGF-R RNAs in day 10 decidua. Con-
versely, expression of the 2.7-kb transcript was greatly
reduced in day 14 embryonic tissue relative to the 9.6- and
5.0-kb receptor transcripts. These data suggest that, consis-
tent with a physiological role, the synthesis of the truncated
receptor is developmentally regulated. Recently, develop-
mental regulation of the expression of an amino-terminally
truncated form of the platelet-derived growth factor receptor
was reported (44). As suggested by these authors, it is
possible that the putative effect of these growth factors on
the developing embryo is modulated by alterations in the
expression of their receptors during development.
The function of the truncated EGF-R is presently un-
known. An important question regarding a potential function
is whether this form of the receptor is able to bind EGF.
Indirect evidence that the human truncated receptor does
bind EGF was provided in a study showing that this receptor
could be eluted by EGF from a monoclonal antibody column
specific for the binding domain of the EGF-R (45). Direct
evidence was provided by the affinity labeling of the trun-
cated receptor with [1251]-EGF (1). However, both of these
studies revealed a 4- to 20-fold lower binding affinity than
that observed for the full-length EGF-R. Preliminary results
from affinity labeling studies in our laboratory indicate that
the rat truncated receptor also binds EGF. Thus, one possi-
bility consistent with the secretion of this form of the
receptor is that it could act as a serum binding protein. Such
a function has been ascribed to a secreted form of the growth
hormone receptor that is also generated by alternative splic-
ing (25, 39). Alternatively, it could modulate the response of
target cells to EGF and transforming growth factor alpha by
competing for these ligands. This is an interesting possibility
in light of a recent report of an astrocyte mitogen inhibitory
activity detected in rat brain and liver extracts (33). This
activity could be abrogated by anti-EGF-R antibodies, sug-
gesting that the inhibitor is immunologically related to the
EGF-R. These data are consistent with the hypothesis that a
secreted form of the EGF-R could modulate normal EGF-R
activity by competition for ligand. A recent study of the
A431 truncated receptor suggests that it not only binds to
EGF but also interacts with full-length receptors to inhibit
activation of the tyrosine kinase. However, this effect was
not attributable to competition for ligand (1). Thus, while the
truncated form of the EGF-R may alter the response of cells
to ligand, it may do so through a mechanism other than
simple competition. Recently, an isoform of the thyroid
hormone receptor generated by alternative splicing was
described (19). This form of the receptor is unable to bind
thyroid hormone or activate thyroid hormone-responsive
genes. However, coexpression of the active and inactive
forms of the thyroid hormone receptor led to inhibition of the
thyroid hormone-inductive effect of the former (21). Forma-
tion of nonfunctional heterodimers of the active and inactive
thyroid hormone receptors was suggested as one possible
mechanism responsible for this inhibitory effect. It was
further proposed that inhibition of hormone action by a
splicing variant of a receptor is a novel mechanism for the
modulation of hormone responsiveness. The truncated form
of the EGF-R could represent another example of such a
regulatory mechanism.
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